March 28th 2024
Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications
June 15th 2017In this article, we look at both metastatic hormone-sensitive and metastatic castration-resistant disease, and we highlight several of the emerging categories of advanced prostate cancer that have direct implications for patient management.
Approved Bladder Cancer Drug Fails to Improve Survival in Confirmatory Trial
May 11th 2017An interim analysis of the phase III IMvigor211 study found that atezolizumab did not meet its primary endpoint of improving overall survival over chemotherapy in patients with locally advanced or metastatic urothelial cancer.
Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.
Reduced, Compressed Chemotherapy Fails in Pediatric Germ Cell Tumors
March 11th 2017Event-free survival was not maintained in children and adolescents with intermediate-risk malignant germ cell tumors when cisplatin-based chemotherapy was reduced from four to three cycles and compressed from 5 to 3 days per cycles.